Search

Displaying results 3401 - 3410 of 9132 in total
  1. Drug

    ICX-RHY

    go.drugbank.com/drugs/DB05716
    Experimental

    ICX-RHY is an investigational therapy comprised of cultured allogeneic fibroblasts.

  2. Drug

    16-Bromoepiandrosterone

    go.drugbank.com/drugs/DB05107
    Investigational

    16-Bromoepiandrosterone is an injectable formulation of a compound called alpha-epi-bromide. … It is a chemical relative of DHEA which was selected for development after it showed antiretroviral activity in laboratory tests.

  3. Drug

    Alinidine

    go.drugbank.com/drugs/DB20618
    Experimental

    Alinidine is a small molecule drug. The usage of the INN stem '-nidine' in the name indicates that Alinidine is a a2 adrenoreceptor agonist. Alinidine has a monoisotopic molecular weight of 269.05 Da.

    Synonyms: St 567 br (as hbr)
  4. Drug

    Goxalapladib

    go.drugbank.com/drugs/DB20736
    Experimental

    Goxalapladib is a small molecule drug. The usage of the INN stem '-pladib' in the name indicates that Goxalapladib is a phospholipase A2​ inhibitor. … Goxalapladib has a monoisotopic molecular weight of 718.29 Da.

  5. Drug

    Indanidine

    go.drugbank.com/drugs/DB20950
    Experimental

    Indanidine is a small molecule drug. The usage of the INN stem '-nidine' in the name indicates that Indanidine is a a2 adrenoreceptor agonist. … Indanidine has a monoisotopic molecular weight of 215.12 Da.

  6. Drug

    Xanomeline

    go.drugbank.com/drugs/DB15357
    ApprovedInvestigational

    Schizophrenia is a complex disease involving a number of different neurotransmitters, including serotonin, dopamine, and acetylcholine. … receptors as opposed to dopamine receptors.

  7. Drug

    Celiprolol

    go.drugbank.com/drugs/DB04846
    ApprovedInvestigationalWithdrawn

    It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. … In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome.

  8. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals.

  9. Drug

    Oportuzumab monatox

    go.drugbank.com/drugs/DB05319
    Investigational

    and a truncated portion of Pseudomonas exotoxin A. … VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells.

  10. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    Fidanacogene elaparvovec is a liver-specific adeno-associated virus (AAV) vector containing a codon-optimized human coagulation FIX gene that was investigated as a potential treatment for hemophilia B. … Current available treatments include substitution therapy involving the intravenous administration of standard factor IX once a week for bleeding or as prophylaxis and 2–3 times a week for severe hemophilia